Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 4/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9669447 | 0.84 | MEN1 (0.42) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL21178072 | 0.84 | MEN1 (0.37) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL7680857 | 0.84 | CYP1A2 (0.40) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL9099943 | 0.84 | KMT2A (0.45) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL1920365 | 0.82 | HSD17B10 (0.48) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL3107564 | 0.80 | MEN1 (0.41) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL7680358 | 0.80 | GABRA1 (0.47) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL11880947 | 0.79 | HSD17B10 (0.60) | ALDH1A1HSD17B10TSHRHPGDCYP1A2 | |
| SCHEMBL8880857 | 0.77 | ALDH1A1 (0.43) | ALDH1A1HSD17B10TSHRCYP3A4HPGD | |
| SCHEMBL3745502 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005301-A1 | SULFONIUM SULFATES, THEIR PREPARATION AND USE | BASF SE (DE) | 2014-01-02 | — | — | US | claimed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |
| WO-2021141807-A1 | METHODS FOR PREPARING MIXED POLYAMIDES, POLYIMIDES AND POLYAMIDEIMlDES VIA HYDROTHERMAL POLYMERIZATION | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2021-07-15 | — | — | WO | disclosed |
| US-20140005301-A1 | SULFONIUM SULFATES, THEIR PREPARATION AND USE | BASF SE (DE) | 2014-01-02 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| US-4931591-A | Novel 5-amino-4-hydroxyvaleryl derivatives | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| US-4138553-A | 3-Methylene cephalosporanic acid derivatives and process for preparation thereof | TEIJIN LIMITED (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885HSD17B10 417/4885TSHR 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.